Key clinical point: Patients with psoriasis had reduced lipid-rich necrotic core (LRNC), a high-risk plaque associated with cardiovascular events, after receiving biologics for 1 year.
Major finding: There was a significant reduction in LRNC 1 year after patients began biologic therapy (median 2.97 mm2; interquartile range, 1.99-4.66) compared with baseline (3.12 mm2; IQR, 1.84-4.35) (P = .028), while patients who did not receive biologic therapy had nonsignificantly higher LRNC after 1 year (median. 3.12 mm2; IQR, 1.82-4.60) compared with baseline measurements (median, 3.34 mm2; IQR, 2.04-4.74) (P = .06).
Study details: A prospective, observational study of CT scans from 209 patients with psoriasis who were treated with biologics in the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative cohort.
Disclosures: This study was funded with support from the National Institutes of Health. One investigator reports financial relationships with numerous pharmaceutical companies. The other authors report no relevant conflicts of interest.
Choi H et al. Circ Cardiovasc Imaging. 2020 Sep;13(9):e011199.